The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus

Journal of International Medical Research

Volumn 35, Issue 3, 2007, Pages 374-383

  Zdarska, Denisa Janickova ^a   Zavadova, E ^b   Kvapil, M ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiotensin Converting Enzyme Inhibitors (ACEI); Cystatin C; Cytokines; Diabetes mellitus; Incipient diabetic nephropathy; Ramipril; Transforming growth factor beta 1; Vascular endothelial growth factor

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HEMOGLOBIN A1C; HOMOCYSTEINE; RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UREA; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MICROALBUMINURIA; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT DURATION;

EID: 34250885139     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500312     Document Type: Article

References (29)

1. Schena FP, Gesualdo L: Pathogenetic mechanism of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 30-33.
2. Yang B, Cros DF, Ollerenshaw M, et al: Polymorphism of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 2003; 17: 1-6.
3. Yan SF, Ramasamy R, Bucciarelli LG, et al: RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res 2004; 1: 10-20.
4. Pickup JC, Willams G: Textbook of Diabetes, 3rd edn. Oxford: Blackwell Science, 2003.
5. Wahab NA, Schaefer L, Weston BS, et al: Glomerulal expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005; 48: 2650-2660.
6. Chambers RC, Leoni P, Kaminski N, et al: Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 2003; 162: 533-546.
7. Boyle JJ: Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005; 3: 63-68.
8. Bacakova L, Herger J, Wilhelm J: Influence of macrophages-modified collagen I on the adhesion and proliferation of vascular smooth muscle cells in culture. Physiol Res 1999; 48: 341-351.
9. Zavadova E, Loercher A, Verstovsek S, et al: The role of macrophages in antitumor defense of patients with ovarian cancer. Hematol Oncol Clin N Am 1999; 13: 135-144.
10. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146.
11. Kanesaki Y, Suzuki D, Uehara G, et al: Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005; 45: 288-294.
12. Vriese AS, Tilton RG, Elger M, et al: Antibodies against vascular endothelial factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
13. Monrozies BP, Rostaing L, Kamar N, et al: The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure. Presse Med 2002; 31: 1714-1720.
14. Viberti G, Mogensen CE, Groop LC, et al: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275-279.
15. The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-593.
16. Sharma K, Eltayeb BO, McGowan TA, et al: Captopril-induced reduction of serum levels of TGF-beta 1 correlates with long-term renoprotection in insulin dependent diabetic patients. Am J Kidney Dis 1999; 34: 951-954.
17. Tamarat R, Silvestre JS, Durie JS, et al: Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest 2002; 82: 747-756.
18. Ye XF, Yorika N, Oda H, et al: Role of transforming growth factor-beta 1 and-beta 2 in ddY mouse nephropathy. J Int Med Res 1997; 25:141-145.
19. Zdarska D, Vavrinec J, Zavadova E, et al: Increased levels of TGF beta 1 in recently diagnosed diabetes mellitus in adults and in patients with diabetic complications. Diabetes 2005; 54: A614.
20. Flores L, Naf R, Hernáez R, et al: Transforming growth factor beta 1 at clinical onset of Type 1 diabetes mellitus. A pilot study. Diabet Med 2004; 21: 818-822.
21. Gilbert RE, Cox A, Wu LL, et al: Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998; 47: 414-422.
22. Sampson MJ, Drury PL: Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body, weight, and serum creatinine. Diabetes Care 1992; 15: 609-612.
23. Perlemoiine C, Beauviex MC, Rigalleau V, et al: Interest of cystatin C in screening diabetic patients for early impairment of renal function. Metabolism 2003; 52: 1258-1264.
24. Buysschaert M, Joudi I, Wallemecq P, et al: Performance of serum cystatin-C versus serum creatinine in subjects with type 1 diabetes. Diabetes Care 2003; 26: 1320.
25. The Diabetes Control and Complications Trial Research Group: The effect of intensive insulin treatment of diabetes in the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
26. Molich ME: The relationship between glucose control and the development of diabetic nephropathy in type 1 diabetes. Semin Nephrol 1997; 17: 101-103.
27. Molyneaux LM, Constantino MI, McGill M, et al: Better glycaemic control and risk reduction of diabetic complications in type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract 1998; 42: 77-83.
28. Steffes MW: Glycemic control and the initiation and progression of the complications of diabetes mellitus. Kidney Int 1997; 63: S36-S39.
29. Border WA, Noble NA: Cytokines in kidney disease: the role of transforming growth factor-beta. Am J Kidney Dis 1993; 22: 105-113.